Growing number of clinical trials in the field of cancer therapies is augment the growth of the Immuno oncology assays market
The immuno-oncology assays are valuable tools in the fight against cancer. These newest methods help to determine how new drugs will interact with existing products and agents, researchers and doctors can design preventative drug plans and better target the treatment of malignant tumors. These assays have been developed to measure the ability of tumor cells to resist various viruses, bacteria, chemicals, and pesticides. These assays are important for both research and pre-clinical development of vaccines, medicines, and drugs.
The
rising prevalence of cancer around the globe is a prime factor driving the
growth of the immuno oncology assays market. According to the World Health
Organization, cancer is the second leading cause of death globally and is
responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6
deaths is due to cancer. The immuno-oncology assay is widely used in clinical
trials because it helps in reducing the cost of research and also improves the
efficiency of therapies. Additionally, these assays enable easy understanding
of the compound’s response intended to mimic the tumor microenvironment. Furthermore,
these assays offer important information to confirm the efficiency of a drug
and also provide easier & faster analysis of cancer. This is further
anticipated to foster the growth of the immuno
oncology assays market.
North
America is expected to gain significant growth over the forecast period and
this is attributed to the increased spending by the government on the research
and development for developing novel drugs and biomarkers. According to the 7
American Medical Association, a recent estimate of cancer drug R&D spending
was $2.7 billion (2017 US dollars). Also, the presence of strong players in the
region such as Thermo Fisher and Illumina, Inc that are highly engaged in the
clinical trials activities is further anticipated to foster the regional market
growth.
Key Developments:
1. 1. In February 2020, Biocare
Medical, a provider of innovative, automated immunohistochemistry (IHC)
reagents and instrumentation, announced the launch of seven novel IVD IHC
antibody markers for clinical diagnostics and research applications.
2. 2. In December 2019, 2cureX AB
announced that the company presented significant progression of the IndiTreat®
test for individualizing immuno-oncological treatment at the ESMO IO Congress.
3. 3. In November 2019, QIAGEN
announced a series of agreements that expand its immuno-oncology assets for
future commercialization of novel companion diagnostics for precision medicine
in immuno-oncology, in particular, based on the powerful next-generation
sequencing (NGS) technology.
Comments
Post a Comment